Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront...

Por Czuczman, M. S., Leonard, J. P., Jung, S., Johnson, J. L., Hsi, E. D., Byrd, J. C., Cheson, B. D.
Publicado no Ann Oncol (2012)

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Por Zinzani, P. L., Vose, J. M., Czuczman, M. S., Reeder, C. B., Haioun, C., Polikoff, J., Tilly, H., Zhang, L., Prandi, K., Li, J., Witzig, T. E.
Publicado em 2013

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

Por Younes, A, Vose, J M, Zelenetz, A D, Smith, M R, Burris, H A, Ansell, S M, Klein, J, Halpern, W, Miceli, R, Kumm, E, Fox, N L, Czuczman, M S
Publicado em 2010